My career is focused on the treatment and prevention of arrhythmias, including both atrial and ventricular tachyarrhythmias. My clinical research has included the role as the P.I. of the arrhythmia adjudication Core Labs of three NHLBI studies. These include the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) ICD-Electrogram (EGM) Core Lab, the AED-EGM Core Lab for the Home Automatic External Defibrillator Trial (HAT) and the ECG Core Lab of the Catheter Ablation versus Antiarrhythmic Drug Therapy in Atrial Fibrillation trial (CABANA). Each of these were pivotal trials which informed arrhythmia management. I am currently the Co-PI of the Biotronik sponsored BIO-LIBRA study, a prospective registry of patients with non-ischemic cardiomyopathy who are indicated for an implantable cardioverter defibrillator. Longer term outcomes on sex and device specific outcomes will be analyzed.
Another focus of my career and research has been to increase the visibility of women in cardiology and promote women into leadership positions. Partnering with medical scientific societies as well as industry sponsors similarly dedicated, this effort has resulted in dramatic change over the past 20 years, both in north America and Europe, as well as in other global regions. A parallel focus has been to bring visibility to the glaring lack of women historically enrolled into clinical trials of arrhythmia therapy.
As Editor-in-Chief of the Heart Rhythm O2 Journal, we publish broadly on arrhythmia topics, including representing authors practicing in developing countries, and authors addressing sex/ethnic/racial specific analyses.